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Abstract
The successful use of transcriptional targeting for cancer 
therapy depends on the activity of a given promoter inside 
the malignant cell. Because solid human tumors evolve 
as a "cross-talk" between the different cell types within 
the tumor, we hypothesized that targeting the entire 
tumor mass might have better therapeutic effect. Secreted 
protein acidic and rich in cysteine (SPARC) is a matricel- 
lular protein overexpressed in different human cancers 
malignant melanomas both in the malignant cells com­
partment as in the stromal one (fibroblasts and endothelial 
cells). We have shown that expression of the herpes 
simplex virus - thymidine kinase (TK) gene driven by the 
SPARC promoter in combination with ganciclovir inhi­
bited human melanoma cell growth in monolayer as well 
as in multicellular spheroids. This inhibitory effect was 
observed both in homotypic spheroids composed of 
melanoma cells alone as well as in spheroids made of 
melanoma cells and stromal cells. Expression of the TK 
gene was also efficient to inhibit the in vivo tumor growth 
of established melanomas when TK was expressed either 
by the malignant cells themselves or by coadministered 
endothelial cells. Our data suggest that the use of 
therapeutic genes driven by SPARC promoter could be a 
valuable strategy for cancer therapy aiming to target all 
the cellular components of the tumor mass. [Mol Cancer 
Ther 2006;5(10):2503-11]
Introduction
In the past several decades, the incidence of malignant 
melanoma has increased more than any other cancer. 
More than 50,000 cases of invasive melanoma (4% of all 
cancer cases) were diagnosed only in the United States in 
2004 (1, 2). Although early, localized disease is effectively 
treated with wide excision, the metastatic disease is 
universally fatal (3, 4). Transcriptional targeting consists in 
the use of tumor-specific gene promoters (TSP) to direct the 
expression of therapeutic genes specifically to a tumor (5). 
The effectiveness of this strategy depends on the precise 
characterization of the tumor-associated gene activity from 
which the TSP derives. In human melanoma, the tyrosinase 
enhancer/promoter and the tyrosine and human melanoma 
inhibitory activity promoters have been used for tissue­
specific expression of therapeutic genes (6-8). Additional 
promoters corresponding to genes expressed in different 
human cancers, such as the survivin and cyclooxygenase-2, 
were also used for targeting malignant melanoma cell lines 
and tumors (9,10). One of the main features of solid human 
tumors is their high heterogeneity in terms of cellular 
composition and gene expression (11). Thus, using a TSP 
whose activity is restricted only to a subset of malignant cells 
where the selected TSP is active might allow remaining 
malignant cells to escape this specific therapy and stromal 
cells to continue supporting malignant cell growth. Thus, 
selecting a TSP for cotargeting the tumor and stromal 
compartments of the tumor mass seems as a plausible 
strategy for achieving a better therapeutic effect.
Secreted protein acidic and rich in cysteine (SPARC) is a 
secreted protein involved in cell-extracellular matrix 
interactions (12). Different groups including ours have 
shown that SPARC overexpression is associated with 
increased aggressiveness and worse prognosis of malignant 
melanoma and other human cancers as well (13-16). 
SPARC was found to be overexpressed not only in 
malignant melanoma cells but also in tumor-associated 
fibroblasts and endothelial cells, whereas moderate or no 
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expression was observed in benign nevi and normal 
melanocytes, respectively (13). In other human cancers, 
such as breast, lung, pancreatic adenocarcinoma, and 
sarcomatoid renal carcinoma, SPARC expression is mainly 
overexpressed by intermingled fibroblasts and endothelial 
cells, although in human breast cancer, it is also overex­
pressed by epithelial cells corresponding to the most 
aggressive cancer types (17-20). Thus, conditional target­
ing of cancer cells using the SPARC gene promoter seems 
as a plausible strategy to target all the cellular components 
of a tumor mass.
To develop a strategy for cotargeting the different cell 
components of a tumor mass, we investigated the charac­
teristics and activity of different variants of the human 
SPARC promoter. We prepared plasmid-based vectors 
carrying the thymidine kinase (TK) gene driven by two 
variants of the SPARC promoter and evaluated their 
efficacy in vitro, in cell culture spheroids, and in vivo after 
xenograft transplantation in nude mice. For the first time, 
we show the antitumor efficacy of this type of construct 
when expressed either by the malignant cells themselves or 
by neighboring fibroblasts or endothelial cells, suggesting 
that the use of therapeutic genes driven by SPARC 
promoter could be a valuable strategy for cancer therapy.
Materials and Methods
Plasmids Construction
A 1.2-kb fragment corresponding to the 5' region of the 
human SPARC gene (—1,175 to +71 bp relative to the 
transcription start site) was amplified from human lym­
phocyte genomic DNA with SPfse and SPfas primers 
(Supplementary Table SI).5 This PCR product, hSPPr, was 
cloned in pGEM-T-easy vector (Promega Corp., Madison, 
WI) to obtain pGEM-hSPPr. This plasmid was used as a 
template to obtain the promoter variants —1,175/+28 (using 
primers SPfse and R28; Supplementary Table SI),5 —120/ 
+28 (using primers F120 and R28; Supplementary Table SI),5 
—120/+71 (using primers F120 and Spfas; Supplementary 
Table SI),5 and hSPPrAlO. The hSPPrAlO promoter variant 
(1,236 bp) corresponds to the promoter lacking the inter- 
GGA box region and was generated by a two-step 
amplification procedure. First, a 1,084-bp fragment up­
stream to the inter-GGA region was amplified using 
primers SPse and AlOr (Supplementary Table SI).5 A 
second fragment (208 bp) downstream to the inter-GGA 
region was amplified with primers AlOf and SPas (Supple­
mentary Table SI).5 Both products were mixed and used as 
templates for a second PCR round with SPse and SPas 
primers to obtain the hSPPrAlO promoter lacking the 10-bp 
inter-GGA region. The four promoter variants were cloned 
in pCR4-TOPO (Invitrogen, Carlsbad, CA) and subcloned 
in the promoterless firefly luciferase gene reporter vector 
pGL3-Basic (Promega) to obtain pGL3-hSPPr, pGL3-120/ 
+71, pGL3-120/+28, and pGL3-hSPPrA10.
5 Supplementary material for this article is available at Molecular Cancer
Therapeutics Online (http://mct.aacrjournals.org/).
The HSVtk gene was amplified from the plasmid 
Pago (21) with TKF1 and TKR1 primers (Supplementary 
Table SI).5 A 1,131-bp fragment was cloned in place of 
the luciferase gene in pGL3-hSPPr and pGL3-hSPPrA10 
followed by subcloning of the Mhil/BamHI hSPPr-TK and 
hSPPrA10-TK cassettes into the Mhil and BamHI sites of 
pcDNA3.1(+) (Invitrogen) in place of the cytomegalovirus 
promoter. The final vectors were named phSPPr-TK and 
phSPPrAlO-TK. The plasmid pcEGFP was constructed by 
cloning the EcoRI/Notl enhanced green fluorescent protein 
(EGFP) entire coding sequence obtained from pEGFP-1 
(Clontech, Mountain View, CA) into the EcoRI/Notl sites of 
pcDNA3.1(+). All the constructs were confirmed by restric­
tion pattern and automatic DNA sequencing (ABI Prism 
377 DNA Sequencer, Applied Biosystems, Foster City, CA).
In vivo Studies
Female athymic N:NIH(S)-nu mice (8-10 weeks old; 
obtained from the animal facility of the Faculty of 
Veterinary, University of La Plata, La Plata, Argentina) 
were s.c. injected in both flanks either with 2.5 x 106 
malignant cells alone or in combination with a similar 
amount of bovine aortic endothelial cells (BAEC). When the 
average tumor volume reached 100 mm3, mice were 
randomly separated in different cages. The corresponding 
groups received i.p. administrations of 30 mg/kg body 
weight of ganciclovir or saline every day during 4 weeks. 
Tumor volumes were estimated from caliper measure­
ments twice weekly [volume = 0.52 x (width)2 x length]. 
None of the mice showed signs of wasting or other visible 
indications of toxicity. Experiments were done following 
institution guidelines. In vivo external imaging was 
followed with a Leica (Wetzlar, Germany) Stereo Fluores­
cence System (model MZFLIII). The animals were kept 
under ethylic ether anesthesia during this process.
Statistical Analysis
Statistical analyses of luciferase studies, spheroid, and 
in vivo experiment were determined by ANOVA followed 
by Tukey's test or Bonferroni's multiple comparison test. 
A P <0.05 was considered significant.
Results
Transcriptional Activity of Different SPARC Promoter 
Variants
SPARC expression was examined in different human cell 
lines by real-time PCR. Compared with A375N, MEL-J-N 
and MEL-Les melanoma cells expressed moderate and low 
SPARC mRNA levels, respectively, whereas HeLa cervix 
carcinoma cells and T-47D breast cancer cells showed 
negligible SPARC mRNA expression (Table 1). WI-38 fetal 
fibroblasts and a transformed variant WI-38 VA expressed 
moderate SPARC mRNA levels, whereas BAEC expressed 
higher SPARC mRNA levels than A375N melanoma cells 
(Table 1).
We next assessed the strength and specificity of the 
different SPARC promoter fragments by comparing their 
ability with direct the expression of the luciferase reporter 
gene in the different cell types (Fig. 1). The —1,175 to +71
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Table 1. Relative expression of SPARC mRNA levels in different 
malignant and nonmalignant cell lines
Cell line Origin Relative expression*
A375N Melanoma 100
MEL-J-N Melanoma 24.29 ± 7.11
MEL-Les Melanoma 7.29 ± 0.70
HeLa Cervix carcinoma 0.08 ± 0.02
T-47D Breast carcinoma 0.11 ± 0.03
WI-38 Fibroblast 18.21 ± 2.68
WI-38 VA Fibroblast 12.68 ± 5.05
BAEC Endothelium 205.19 ± 12.35
'Data were obtained by real-time PCR and expressed as tile relative 
expression with respect to the levels observed in the A375N cell line. The 
numbers correspond to the mean ± SD.
SPARC promoter fragment (termed hSPPr) includes 
the entire nontranslated first exon that was shown to 
contain positive regulatory elements in the bovine SPARC 
promoter (22). This construct was compared with a variant 
extending from —1,175 to +28 that was shown to display 
high activity (23), a shorter variant extending from —120 to 
+28 that was also shown to drive gene activity (23), and to 
a variant extending from —120 to +71 that includes the first 
exon. All the promoter fragments were active in A375N 
melanoma cells; however, hSPPr displayed the highest 
specificity being 4-and 3-fold more active in A375N cells 
than in T-47D and HeLa cells, respectively (Fig. 1A). The 
rest of the promoter fragments showed similar or even 
higher activity than hSPPr in A375N cells but their activity 
did not correlate with SPARC expression levels in the 
different cell types (Fig. 1A).
We pursued the characterization of hSPPr activity by 
deleting a 10-bp spacer between the GGA-1 and GGA-2 
boxes [termed hSPPr(AlO)] that has been shown previously 
to inhibit promoter activity (23). hSPPr(AlO) activity was 
4- to 15-fold higher than hSPPr in melanoma cells, WI-38 
cells, and BAEC, although it also showed 4-fold increased 
activity in T-47D cells (Fig. IB). As a comparison, we show 
the levels of activity of an SV40 promoter that was highly 
variable depending on the cell type (Fig. IB).
TK Expression Driven by SPARC Promoter followed 
by Exposure to Ganciclovir-Induced Human Melanoma 
Cell Killing In vitro
We constructed two plasmids carrying the TK gene 
under the control of either hSPPr or hSPPr(AlO) promoters. 
A375N cells were transfected with both constructs and at 
least 10 G418-resistant clones were selected and tested for 
their sensitivity to different concentrations of ganciclovir 
(1, 5, and 50 pmol/L). All the isolated clones were highly 
sensitive to ganciclovir, regardless of whether TK was 
driven by hSPPr or hSPPr(AlO) promoters (data not 
shown). One stable clone was selected and further 
characterized in each case and named Mel-TK and Mel- 
(AIO)-TK, respectively. Mel-(A10)-TK cells were slightly 
more sensitive than Mel-TK cells to the lowest ganciclovir 
concentration, although at higher ganciclovir concentra­
tions, both promoters were equally effective in inhibiting 
melanoma cell growth in vitro (Fig. 2A). Semiquantitative 
reverse transcription-PCR analysis showed 2-fold higher 
TK activity in the Mel-TK than in the Mel-(A10)-TK selected 
cell clone (Fig. 2A, inset); this difference might account for 
the fact that both cell clones were almost equally sensitive 
to ganciclovir both in vitro and in vivo (see Fig. 5 below) 
despite the fact that hSPPr(AlO) activity was higher than 
hSPPr in melanoma cells according to luciferase assays.
Additional studies showed that 20% of Mel-TK or Mel- 
(AIO)-TK cells mixed with 80% of parental A375N cells 
were sufficient to eliminate >50% of total cells in both cases 
in the presence of 50 |imol/L ganciclovir, indicating that 
SPARC promoter was able to drive TK bystander effect 
efficiently (Fig. 2B). Moreover, TK expression in melanoma 
cells induced 55 ± 3.6% and 81 ± 2.5% inhibition in total 
cell growth when a coculture of Mel-(A10)-TK either 
with BAEC or WI-38 VA cells (1:1 ratio) was exposed to 
50 |imol/L ganciclovir, suggesting that TK expression in 
melanoma cells induced killing of adjacent nonmelanoma 
cells (Fig. 2C).
TK Expression Driven by SPARC Promoter followed 
by Exposure to Ganciclovir-lnhibited Melanoma Cell 
Growth in Homotypic and Heterotypic Spheroids
We next did in vitro assays using a three-dimensional 
model system of multicellular spheroids (24). Spheroids 
were grown for 3 days followed by the addition of 
ganciclovir and sized 7 days later. Homotypic spheroids 
made of 100% of either Mel-TK or Mel-(A10)-TK cells were 
growth inhibited at the three ganciclovir concentrations 
tested (Fig. 3A and B). Interestingly, when TK-expressing 
A375N cells accounted for only 20% of total A375N cells, 
spheroid growth was inhibited close to 80% in the presence 
of 50 |imol/L ganciclovir, confirming that TK expression 
driven by SPARC promoter can promote a bystander effect 
also when cells were grown in spheroids (Fig. 3A and B). 
In addition, both Mel-TK and Mel-(A10)-TK cells led to a 
strong growth inhibition of heterotypic spheroids com­
posed of either of the two cell clones mixed with WI-38 cells 
or BAEC, confirming that TK expression in melanoma cells 
led to the elimination of neighbor stromal cells (Fig. 3C). In 
the entire set of experiments, ganciclovir had only minimal 
effect on spheroid growth in the absence of TK expression 
(data not shown).
TK Activity Expressed in Endothelial Cells Led to Cell 
Growth Inhibition in the Presence of Ganciclovir
As an initial step to establish whether TK expression in 
nonmelanoma cells driven by SPARC promoter might 
affect melanoma cell growth, we stably transfected WI-38 
VA cells and BAEC with plasmids expressing TK. WI-38 
cells were not used due to their low levels of trans- 
fectability (data not shown). Stable transfection of WI-38 
VA cells and BAEC with hSPPr(A10)-TK plasmid led to the 
elimination of almost 70% of cells in both cases in the 
presence of 50 |imol/L ganciclovir (Fig. 4A).
Next, we established whether TK expression by WI-38 
VA cells and BAEC might affect growth of adjacent cells 
lacking TK expression. A heterotypic cell culture mix of 
BAEC-(A10)-TK and A375N cells (1:1 ratio) was growth
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Figure 1. Luciferase activity driven by different variants of SPARC promoter. A, activity of different variants of SPARC promoter in different cell lines 
B, activity of hSPPr and hSPPr(A10) in different cell types. Statistical analysis of hSPPr and hSPPr(A10) activity in the different cell lines was made in 
comparison to T-47D cells. ***, p < 0.001; **, P < 0.01; *, P < 0.05. Data include the activity in the different cell types of an SV40 promoter.
inhibited by 54 ± 1.8% in the presence of ganciclovir 
(Fig. 4B). In comparison, an heterotypic cell culture mix of 
WI-38 VA-(A10)-TK and A375N cells (1:1 ratio) was growth 
inhibited only by 40 ± 6.2% (Fig. 4B), suggesting that 
TK expression was more effective in driving elimination 
of melanoma cells when expressed by endothelial cells. 
In addition, BAEC-(A10)-TK inhibited by 68.9 ± 2.3% the 
in vitro growth of a 1:1 cell culture mix containing WI-38 
VA cells (Fig. 4B), whereas WI-38 VA-(A10)-TK cells 
inhibited by 68 ± 3.4% a 1:1 cell culture mix containing 
BAEC (Fig. 4B).
Next, we try to establish whether TK expression in BAEC 
could be also effective in achieving elimination of malig­
nant cells lacking TK expression in heterotypic spheroids. 
BAEC and BAEC-(A10)-TK cells were unable to form 
homotypic spheroids (data not shown); however, BAEC- 
(AIO)-TK cells readily formed spheroids when mixed at 1:1 
ratio with malignant cells. Exposure of these heterotypic 
spheroids to ganciclovir led to a growth inhibition of 
37.6 ± 5.6%, 33.7 ± 6.2%, and 22.6 ± 3% when spheroids 
contained MEL-EGFP, T-47D, or HeLa cells, respectively 
(Fig. 4C). WI-38-(A10)-TK cells were slightly less effective 
than BAEC-(A10)-TK cells in the inhibition of heterotypic 
spheroids containing the malignant cells described above 
(data not shown). We hypothesized that the weaker 
inhibitory growth effect of stromal cells expressing TK in 
heterotypic spheroids compared with cell culture mixes 
could be due to the way the cells arranged in the spheroid. 
Interestingly, Mel-EGFP cells located in the outer part of 
the spheroid, whereas BAEC-(A10)-TK cells concentrated in 
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the inner part and were then less accessible to ganciclovir 
(Fig. 4D). Immunohistochemical detection of proliferating 
cell nuclear antigen in combination with EGFP expression 
also showed that both Mel-EGFP and BAEC-(A10)-TK cells 
were cycling (Fig. 4E and F). Very similar results were 
obtained with heterotypic spheroids made of WI-38 
VA-(A10)-TK and Mel-EGFP cells (data not shown).
Expression of TK Driven by SPARC Promoters fol­
lowed by Ganciclovir Administration Led to the In vivo 
Growth Inhibition of Human Melanomas in Nude Mice
As a first approach to establish the feasibility of using 
SPARC promoter-TK combination in cancer therapy, we 
established in vivo models, in which Mel-TK cells were s.c. 
xenografted bilaterally in nude mice. Ten days later, mice 
harboring established melanoma tumors were split in two 
and given daily with either ganciclovir or PBS for 28 days. 
No tumor regression was observed in the groups of mice 
that received PBS (Fig. 5A). However, tumor regression 
was observed in all mice treated with ganciclovir (Fig. 5A). 
Average tumor size at the end of the experiment was 
below the size observed at the initiation of ganciclovir 
administration and in most cases tumors were not visible 
(Fig. 5A).
Mel-EGFP tumors also grew rapidly regardless of 
ganciclovir administration, whereas the in vivo growth of 
tumors composed of 1:1 mix of Mel-TK and Mel-EGFP cells 
was strongly inhibited following ganciclovir administration 
compared with control Mel-TK/Mel-EGFP tumors treated 
with PBS (Fig. 5A). Twenty-eight days after the initiation of 
the experiments, a decrease in the amount of EGFP- 
expressing cells was observed by external visualization of 
EGFP fluorescence in the group of mice treated with 
ganciclovir (Fig. 5B). As expected, mice injected with a mix 
of Mel-TK and Mel-EGFP cells and treated with PBS 
showed large tumors (Fig. 5B). Similar studies done with 
melanoma cells expressing TK driven by the hSPPr(AlO)
B
c
References
^■1 control
I------1 1 pM gcv
I------1 5 |JM GCV
I------1 50 pM GCV
Figure 2. In vitro sensitivity to ganciclovir (GCV) of different cell types expressing TK. A, ganciclovir sensitivity of A375N-derived cell clones expressing 
TK driven by hSPPr and hSPPr(AIO). Inset, TK and actin (ACTB) bands after semiquantitative reverse transcription-PCR. B, bystander effect induced by 
melanoma cells expressing TK driven by the two versions of SPARC promoter. C, ganciclovir sensitivity of a cell culture mix composed of Mel-(A10)-TK and 
either BAEC or WI-38 VA cells (1:1 cell ratio). ***, P < 0.001.
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Figure 3. In vitro sensitivity to ganciclovir of homotypic and heterotypic spheroids. A, ganciclovir sensitivity of spheroids made of Mel-TK cells alone or 
mixed with Mel-EGFP cells. B, ganciclovir sensitivity of spheroids made of Mel-(A10)-TK alone or mixed with Mel-EGFP cells. C, ganciclovir sensitivity of 
spheroids made of melanoma cells expressing TK mixed with WI-38 fibroblasts, or BAEC.
promoter also showed inhibition of tumor growth follow­
ing ganciclovir administration, indicating that both variants 
of SPARC promoter were useful in driving TK expression 
leading to tumor growth inhibition (Fig. 5C).
TK Expression Driven by Endothelial Cells followed by 
Ganciclovir Administration Led to the In vivo Growth 
Inhibition of Established Tumors Composed of Melano­
ma and Endothelial Cells
To establish whether expression of TK by adjacent 
endothelial cells might induce tumor growth inhibition 
in vivo, we injected mice s.c. with a mix of BAEC-(A10)-TK 
cells and Mel-EGFP melanoma cells. Although these 
heterotypic tumors were smaller than those observed with 
melanoma cells alone, they grew uniformly and reached an 
average size of 200 mm3 (Fig. 5D; data not shown). 
Expression of TK by coadministered BAEC inhibited tumor 
growth in vivo in xenograft models following ganciclovir 
administration (Fig. 5D). Tumor regression was observed 
in all mice and average tumor size at the end of the 
experiment was below the size observed at the initiation 
of ganciclovir administration and in most cases tumors 
were not visible (Fig. 5D; data not shown).
Discussion
Conditional expression of therapeutic genes in tumor cells 
driven by TSP is a promising approach for cancer 
treatment. Promoters are currently selected for their 
capacity of being expressed mainly by the malignant tumor 
cells themselves (5-7). Because tumor progression occurs 
as a result of an active cross-talk between malignant and 
tumor-associated stromal cells, we hypothesized that 
expression of therapeutic genes driven by promoters 
corresponding to genes activated in the different cell types 
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that compose the tumor mass would provide a greater 
advantage to achieve cancer remission. Here, we show for 
the first time that expression of a suicidal gene in 
nontumorigenic endothelial cells or fibroblasts driven by 
the SPARC promoter was able to inhibit melanoma cell 
growth both in vitro and in vivo in xenogeneic models.
Different promoter variants of the SPARC gene were 
evaluated to establish their degree of activity and specific­
ity. We observed that the largest fragment (hSPPr) showed 
the better ratio of specificity versus activity, being more 
active in cells expressing the highest SPARC mRNA levels. 
Interestingly, a certain threshold of endogenous SPARC 
mRNA expression was necessary to establish a clear 
difference in hSPPr activity between cells that expressed 
SPARC mRNA compared with cells lacking SPARC mRNA 
expression. Indeed, MEL-Les cells that expressed only 7% 
of SPARC mRNA levels expressed by A375N cells showed 
only 1.8-fold higher hSPPr activity than T-47D cells, 
whereas MEL-J-N cells that expressed 24% of SPARC 
mRNA levels expressed by A375N cells showed 5.5-fold 
higher hSPPr activity than T-47D cells. In addition, we 
found no strict correlation between endogenous SPARC 
mRNA levels and promoter activity. Indeed, A375N, MEL- 
J-N, and WI-38 VA cells and BAEC that expressed different
A B
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ZJ 
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8 (D > 50-
7BO' 25-
0J II
BAEC-(A10)-TK WI-38 VA-(A1O)-TK BAEC-(41O)-TK 50% 50% 0% 0%
WI-38 VA-(A1O)-TK 0% 0% 50% 50%
Mel 50% 0% 50% 0%
WI-38 VA 0% 50% 0% 0%
BAEC 0% 0% 0% 50%
c
Figure 4. In vitro sensitivity to ganciclovir of heterotypic cell cultures and spheroids containing stromal cells expressing TK. A, ganciclovir sensitivity of 
BAEC and WI-38 VA cells expressing TK. In all cases, ganciclovir was added for 5 d, the day after cells were seeded on the plates; data were obtained by 
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. B, ganciclovir sensitivity of cells monolayers containing BAEC-(A10)-TK or WI-38 
VA-(A10)-TK cells mixed with A375N cells. C, ganciclovir sensitivity of heterotypic spheroids made of BAEC-(A10)-TK cells mixed with different malignant 
cell types. D, immunofluorescence of a heterotypic spheroid made of Mel-EGFP and BAEC-(A10)-TK cells showing the presence of Mel-EGFP green 
fluorescent cells at the outer part. E, combined immunofluorescence of EGFP and proliferating cell nuclear antigen on a spheroid made of Mel-EGFP and 
BAEC-(A10)-TK cells. A representative Mel-EGFP cell {arrow) showing a blue nucleus (corresponding to positive proliferating cell nuclear antigen staining) 
and green cytoplasm. F, similar to E but showing a potential BAEC-(A10)-TK cell {arrow) with a blue nucleus and no green fluorescence in the cytoplasm.
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Figure 5. In vivo inhibition of established melanomas expressing TK and treated with ganciclovir. A, the different cell types were injected as described 
and treated with PBS (n = 4) or ganciclovir (n = 6). B, external visualization of the in vivo tumor growth (bright field and fluorescence). C, mice carrying 
Mel-(A10)-TK tumors were treated with ganciclovir (n = 6) or PBS (n = 4) as described. D, mice carrying chimeric BAEC-(A10)-TK:A375N tumors were 
treated with ganciclovir (n = 6) or PBS (n = 4) as described.
SPARC mRNA levels showed essentially similar levels of 
hSPPr activity. By searching the literature, we found no 
reports assessing the correlation between endogenous 
expression levels of a given gene and the activity of the 
corresponding promoter which is of relevance when select­
ing a promoter for conditional targeting (7, 9, 25, 26). We 
can hypothesize that additional regulatory elements im­
portant in the regulation of endogenous SPARC mRNA 
levels, including post-transcriptional regulation and intra­
cellular stability of the mRNA, are absent in hSPPr and 
may give origin to the lack of strict correlation between 
SPARC mRNA levels and promoter activity.
In close agreement with a previous report (23), deletion of 
the 10-bp inter-GGA spacer element has an up-regulatory 
effect on SPARC promoter activity. However, the promoter 
fragment lacking the inter-GGA 10 bp was still more active 
in cells expressing SPARC. Despite the differences in acti­
vity between the two large promoter fragments in luci­
ferase studies, both were able to drive TK expression and 
induce tumor cells elimination, both in vitro and in vivo.
The present studies that compared SPARC promoter 
capacity with drive TK expression in vitro in cell culture 
and multicellular spheroids and in vivo allowed drawing 
interesting conclusions: both SPARC promoter variants 
were effective in driving TK expression inducing growth 
inhibition of homotypic melanoma spheroids and tumors 
in the presence of ganciclovir. SPARC promoter-driven TK 
expression in melanoma cells was able to inhibit hetero­
typic spheroids containing, in addition, fibroblasts or 
endothelial cells. Rather than the phagocytosis of melano­
ma apoptotic bodies by neighbor fibroblasts or endothelial 
cells, which is not an intrinsic feature of these cells, this 
result suggests that tight junctions can be formed between 
malignant and stromal cells that allow exchange of phos­
phorylated ganciclovir (27-29). Vasculogenic mimicry, a 
process by which cancer cells can adopt the functionality 
of endothelial cells, has been characterized in human 
melanoma cells showing their intrinsic plasticity and 
potential capacity for tight interaction with neighbor 
endothelium (30).
Most importantly, the in vivo growth inhibition of mixed 
tumors composed of melanoma and endothelial cells was 
also attained when TK was expressed by the coadminis­
tered endothelial cells. A previous study has shown that 
expression of TK in pluripotent bone stromal cells driven 
by the osteocalcin promoter was effective in inhibiting the 
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in vivo growth of chimeric tumors made of bone stromal 
cells and prostate cancer cells expressing osteocalcin (28). 
However, this previous work did not provide evidence 
about the efficacy of the approach on the complete set of 
animals, the extent of the in vivo growth inhibition, and the 
potential tumorigenic capacity of the pluripotent bone 
stromal cells that contributed a bone component to the 
chimeric tumors. The larger efficacy of BAEC-(A10)-TK 
in vivo and in monolayer cell culture compared with 
multicellular spheroids was probably the result of BAEC- 
(AIO)-TK cells accessibility to ganciclovir due to spheroid 
architecture. Previous studies showed that binding of 
cytostatic drugs at the spheroid periphery delayed or 
prevented drug penetration to the inner part of the 
spheroids (31). It can be hypothesized that TK was more 
effective in vivo than in spheroids when expressed by 
BAEC, most probably due to tumor accessibility to 
ganciclovir through tumor-associated vasculature. Overall, 
the evidence that the in vivo melanoma growth was 
inhibited even when TK was expressed by neighbor 
endothelial cells suggests that targeting the endothelial cell 
compartment with a therapeutic vector whose activity is 
driven by SPARC promoter might achieve tumor elimina­
tion even if the malignant cell compartment of the tumor 
mass showed no SPARC activity.
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